Caribou Biosciences’ latest pivot to immunology is not going to plan. The cell and gene therapy company is laying off nearly one-third of its workforce and ending work on its lupus pipeline, according to an SEC filing April 24. That leaves the Berkeley, California–based biotech with just two remaining assets, both allogeneic, or “off-the-shelf,” CAR T products for a variety of different cancers. Caribou expects the layoffs to be mostly done by the end of the second quarter. The cuts affect 47 employees, representing 32% of the company’s staff.